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    Mice were irradiated with gamma-rays under high dose rate (42 r per second) and 
 were treated with isologous, homologous, and heterologous bone marrow in various experi-
 mental conditions not reported in the previous study. By increasing the dose of isologous 
 bone marrow from 10 x106 to 20 x106 nucleated cells, a fairly good survival rate was ob-
 tained even when isologous bone marrow (IBM) was injected at as late as 6 days after ir-
 radiation. Even with this dose IBM injection at 7 days was not effective in obtaining 
 surviving mice. The IBM dose as small as 0.1 x106 nucleated cells was effective in obtain-
 ing fairly good survival rate when IBM was given immediately after irradiation. However, 
 larger IBM dose is desirable because of quicker regeneration of hematopoietic organs in 
 mice receiving a larger dose. The quick recovery of hematopoietic organs in mice lethally 
 gamma-irradiated and treated with IBM demonstrated previously by hematological and 
 histological study was also proved chemically by the early incorporation of formate-C' into 
 the bone marrow and spleen after irradiation. Iron metabolism in irradiated and IBM 
 treated mice was also studied. The delayed treatment with homologous bone marrow (HBM) 
 from one to four days post-irradiation seemed effective in obtaining a good initial 14 day 
 survival rate. Heterologous rat bone marrow (RBM) has so far been ineffective even by 
 changing experimental conditions variously. 
    As one of the means of facilitating take of foreign bone marrow and of preventing se-
 condary disease, combined use of AET protection and bone marrow treatment was tried. 
 When homologous donor mice were given AET followed by 500 r (or 100 r) irradiation, 
 neither initial nor subsequent survival of lethally irradiated recipient was good. When 
 recipient mice were given AET followed by an otherwise supralethal dose of irradiation 
 (1500 r) good initial survival was obtained. 
    Bone marrow dose not seem to modify radiation damage to tissues other than those of 
 the hematopoietic system as shown by retarded growth and reduced life span. Further-
 more, evidences of late radiation effect such as nephrosclerosis and calcification of myocar-
 dium were observed in gamma-irradiated and IBM treated mice. 
                          INTRODUCTION 
   In this atomic era one may be exposed any time to a large dose of radiation 
instantaneously. The very potent Co" irradiation facility available to us can 
irradiate mice lethally within half a minute. Previous studies on bone marrow 
  * 0-1*T1 ,, 1 Fi , fi)II r , 1115JT tgi, [BA 
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treatment in mice lethally gamma-irradiated under high dose rate has been 
 reported"2'3'. Experimental conditions in bone marrow treatment were chang-
ed variously to observe their effect on the survival of mice. Further, experi-
ments were directed toward finding out measures of preventing so-called socon-
dary disease which is a major limiting factor of successful bone marrow trans-
plantation. The results of preliminary studies obtained to the present time is to 
be reported here.* 
                     MATERIALS AND METHODS 
   Dd/s strain mice supplied from the Kyoto University Inbred Animal Center 
were used in IBM treatment study and as recipients in HBM and RBM treatment 
study. Other animals used were na 2 and CF$f1 mice and Wistar and Sprague-
Dawley rats. These mice and rats were 2 to 3 months old unless specified. The 
method of obtaining mouse bone marrow suspensious and the conditions of irra-
diation were described elsewhere,'. All mice were irradiated under the dose 
rate of approximately 42 r per second at place A of the Co" gamma-irradiation 
facility1i10 "Lethal" irradiation in this study means approximately 900 r ir-
radiation which is 100% lethal to mice within 30 days. In order to obtain rat 
marrow suspensions, bilateral femurs and tibias were removed aseptically and 
cut longitudinally, and marrow was scraped off and suspended in Tyrode's solu-
tion. The suspension was stirred up, gently centrifuged to remove supernating 
fat, and filtered through several layers of gauze. Bone marrow suspensions were 
injected intravenously within several hours after irradiation unless otherwise 
indicated. 
                    RESULTS AND DISCUSSION 
   I. Delayed IBM Treatment (Table 1) 
   When the dose of IBM given was approximately 10x 10°, IBM given at 5 days 
after irradiation resulted in poor 30 day survival rate°. In this study the 
dose was doubled to 20 X10' nucleated cells. The survival rate was good at 5 
    Table 1. Survival rate of 900r+20 x 106 IBM mice at various post irradiation days. 
  Days afterNo. of Survival/No. of Irradiated (at days)% Survival 
 irradiation 7 14 21 30 609030 90 
   56/6 6/6 6/6 6/6 6/6 6/6 100 100 
    67/10 5/10 4/10 4/10 3/10 3/10 40 30 
 79/10 0/100 0 
   * The results reported in this paper was presented before the symposium on bone mar-
    row transplantation held by the Japan Hematological Society in November, 1961 in 
Tokyot"". 
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days and fairly good at 6 days. IBM treatment at 7 days with this double dose 
was not effective, however. Recovery of body weight seemed to be retarded 
when the interval between irradiation and bone marrow treatment was longer 
(Fig. 1). 
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  Fig. 1. Body weight change of 900 r+20 x106 IBM mice at various post irradiation days. 
   II. The Effect of IBM Dose on 30 Day Survival (Table 2) 
   When the standard dose of IBM (5 to 10 x106 nucleated cells) is given, 40 to 
100% 30 day survival is expected to be obtained. How is the survival rate when 
the dose is changed ? In this study the dose was changed from 20 X106 to zero. 
One million cells gave good survival. It was rather a surprise to note that 0.1 x 
106 cells still gave fairly good 30 day survival. When all cells were removed 
by filtering bone marrow suspensions through Seitz filter, there was no survival 
and accelerated recovery of hematopoietic organs was not observed either histolo-
gically or hematologically. Although survival rate in the group receiving rela-
  Table 2. Survival rate of lethally irradiated mice treated with various amount of IBM. 
       Amount of IBM                         No. of Survival/No. of Irradiated (at days),°%Survival 
(Nucl. cell count) 7 14 21 30 60 90 30 90 
  1 20 x 106 11/11 11/11 11/11 10/11 9/11 9/11 91 82 
  2 l x l0° 11/11 11/11 9/11 9/11 9/11 9/11 91 82 
  3 0.1 x 106 11/11 7/11 5/11 5/11 5/11 4/11 45 36 
40* 7/7 0/70 
  * Filtrate through Seitz filter of IBM suspension. 
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Fig. 4. Body weight change in lethally irradiated mice treated with various amount of IBM. 
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tively small dose of IBM was fairly good, recovery of nucleated cell count in the 
femoral marrow, of spleen weight and of body weight was faster in the group 
receiving larger dose (Figs. 2, 3 & 4). 
   III. Nucleic Acid Metabolism in Lethally Gamma-Irradiated Mice Treated 
       with Isologous Bone Marrow 
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        Fig. 6. Formate-C'4 incorporation into uncleic acid bases in bone marrow. 
( 46 )
 BoneNarrow Treatment of Mice Lethally Irradiated with Gamma-Rays 
               RNA Adenine 
                CPM /uMol. 
1000 
O 
    800 °„ O 
                600` 
       400or, 
200 
0             N
ormal 0 24 hrs.8 
DNA Thymine 





         200\O^'~ 
                0
Norm4 0 24 hrs.B days 
: Normal 
•---.: Control 
I B M 
           Fig. 7. Formate-C'1 incorporation into nucleic acid bases in spleen. 
   To demonstrate chemically the early regeneration of hematopoietic organs in 
irradiated and IBM treated mice, incorpoation of formate-Cl" into nucleic acid 
bases of bone marrow and spleen in them was studied. Four hours after intra-
peritoneal injection of 2.5 pC of formate-C1" solution, bone marrow suspensions 
and spleen homogenate were made for uptake study. The incorporation of for-
mate-C1" into DNA thymine and RNA adenine in bone marrow and and spleen 
was slightly higher in IBM treated mice than the irradiated control already at 
24 hours after irradiation. The difference was apparent at 8 days (Figs. 5, 6 & 
7). The tendency that the recovery of formate-C1" incorporation in IBM treated 
mice was faster than that of nucleated cell counts suggests that recovery of 
nucleated cells was mainly due to an increase of immature blood cells. 
   IV. Iron Metabolism in Lethally Gamma-Irradiated and IBM treated Mice 
Fe19 incorporation in red cells of lethally irradiated and IBM treated mice 
was studied (Fig. 8). One pC of Feo9 per mouse was injected intravenously from 
one to 24 days after gamma-irradiation and IBM treatment, followed by serial 
collection of blood for observing Fe59 incorporation in red cells. The incorpora-
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      Fig. 8. Fe59 incorporation in red cells of lethally irradiated IBM treated mice. 
tion was considerably depressed within several days after irradiation followed 
by gradual recovery, and was almost normal at 22 days. 
   V. Delayed Homologous Bone Marrow Treatment (Table 3). 
   Homologous bone marrow was injected one to for days after lethal gamma-
irradiation to know if there was any beneficial effect on survival. Serum anti-
body formation as manifested by hemolysin formation has been reported to be 
minimum at 24 to 48 hours after irradiation" and, furthermore, acellular or 
hypocellular marrow cavity could be better mechanically for donor marrow cells 
to seed and repopulate there than normo-celluar marrow. Immediate treatment 
  Table 3. Survival rate of lethally gamma irradiated mice treated with 10x106 HBM 
    at various post irradiation days. 
  Days afterNo. of Survival/No. of Irradiated (at days) % Survival 
 irradiation 7 14 21 30 60 90 120 21 90 
   1 7/9 7/9 3/9 3/9 3/9 3/9 3/9 33 33 
   2 8/9 6/9 2/9 2/9 2/9 2/9 0/9 22 22 
  3 7/10 4/9 3/9 2/9 0/933 0 
    4 7/10 6/10 3/10 2/10 2/10 1/10 1/10 30 10 
 control 3/6 1/6 0/60 
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with HBM after  900  r gamma-irradiation usually gives, in our study2), less 
than 50 or 60(V14 day survival. As seen from Table 3, 14 day survival was 
good when HBM was given one, two, and four days after irradiation. However, 
subsequent surival rate was low as in the case of immediate treatment. HBM 
treatment at 5 days after lethal irradiation in the pigeon was reported to have 
elongated mean survival time12' . Therefore further delaying bone marrow 
treatment would be worthwhile trying. 
   VI. Heterologous (Rat) Bone Marrow (RBM) Treatment 
   RBM treatment has, so far, been ineffective even by changing experimental 
conditions variously (Table 4). In experiment 2, 3, 4, 5, 6, 7 and 8, the dose of 
 Table 4. Survival rate of gamma-irradiated mice treated with heterologous bone marrow. 
                    Radiation No. of cell No. of Survival/No. of Irradiated (at days) 
     Donor Recipient dose injected 
             (r) (x 106)7 14 21 30 60 90 
122 MosNa900 14^ 25T : 12/14 9/14 0/14  Wist. RatC : 9/9 0/9 
22 MosNaz 900 42T : 14/20 0/20   Wist. Rat--C : 8/10 0/10 
  1 MosT : 9/12 0/12 3 
Wist. Ratdd/s900 15 C : 4/8 0/8 
42 1\4osdd/s780 18T:6/14 0/14  Wist. RatC : 6/8 1/8 0/8 
   2 Mos dd/s1100 37T:0/14*  Wist. RatC : 0/11 
  2 MosAETT : 3/8 1/8 1/8 1/8 1/8 1/8 6 
Wist. Ratdd/s130070C : 5/9 5/9 2/9 2/9 2/9 1/9 
72 Mos dd/s 900 200 T : 3/3 0/3      Sp-Dow. 
82 Mos CFI 900 200 T : 3/3 3/3 1/3 0/3     Wist. Rat Na                     2 
   * 0.25 mg/mouse of hydrocortisone daily for 3 days. 
RBM was increased to 42 x106, young rats were used, relatively smaller dose of 
irradiation was given, irradiation dose was increased to 1100 r, AET was given 
10 minutes prior to 1300 r irradiation, a large dose of bone marrow (20 X106) was 
used, and recipient mice were changed from dd/s to CF##1 and na2 together with 
administation of 20x10° cells, respectively all were without effect. In any mice 
surviving at 2 weeks after irradiation and RBM treatment, alkaline phosphatase 
positive neutrophils were not found in the peripheral blood indicating no evidence 
of take of rat marrow in the mice. In regard to many papers reporting succes-
sful transplantation of RBM into mice4`10', further study is needed to find out 
the cause of this failure in the experimental conditions described here. 
   VII. A Few Trials to Facilitate Implantation of Bone Marrow and to Preclude 
        Secondary Disease 
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   Delaying bone marrow treatment, use of steroids and changing bone marrow 
dose as part of the means to facililate implantation of homologous (heterologous) 
bone marrow and to preclude so-called secondery disease have been described. 
In a study of giving a double dose (20x106 cells) of HBM, no better 14 day sur-
vival was obtained. 
   AET (S, 2-aminoethylisothiourea dihydrobromide) has been known to be ef-
fective in protecting animals from radiation injury. AET is also deduced that 
it protects predominantly non-antibody forming cells13'. Although this deduc-
tion is based on the experiment dealing with circulating serum antibody for-
mation and not with cellular antibody formation which plays an important role 
in transplantation immunity, combined use of chemical protection and bone mar-
row treatment would be worthwhile to try. The results of a preliminary study 
in regard to this combined use are to be reported as follows : 
   Table 5. Survival rate of lethally (900 r) gamma-irradiated mice treated with homo-
    logous bone marrow (or spleen) from the mice given AET (10.0 mg) and 500 r (or 
    100 r). 
                                          Survival rate (at days) 
                   7 14 21 30 60 90 
AET +500 r 900 r HBM 9/12 4/12 4/12 4/12 1/12 1/12 
        Na2 ------> dd/s  1H.spl 7/8 0/8 
AET+100 r 900 r HBM 8/10 3/10 3/10 1/10 1/10 0/10 
  2b 
      Naz ---> dd/sH.spl 5/8 2/8 2/8 1/8 1/8 
     500 r 900 r HBM 3/5 0/5 
 3 ~ 
Na2 --------> dd/sH.spl 4/6 2/6 2/6 2/6 1/6 
     100 r 900 r HBM 6/6 1/6 0/6 
  4 
Na2 -----dd/s H.spl 5/6 3/6 1/6 1/6 1/6         --> 
   a) Homologous donor mice are injected with AET (10 mg. per mouse) fol-
lowed by 500 r (or 100 r) of gamma-irradiation 10 minutes later. By this proce-
dure antibody forming cells of the donor is incapacitated leaving relatively intact 
nonantibody forming cells. Therefore, the graft to host reaction, if it occurs, in 
secondary disease may be prevented to develope. The recipient mice were ir-
radiated with 900 r of gamma-rays followed by the intravenous injection of bone 
marrow of the donor mice treated as described. The result is shown in Table 
5. Neither initial 14 day nor subsequent 30 or 60 day survival was good. Irra-
diation dose to the donor mice may be too large an amount killing or incapacitat-
ing non-antibody forming cells as well as antibody forming cells. 
   b) Recipient mice are injected with AET (6.5 mg. per mouse) followed by 
a large dose of gamma-irradiation. The dose of irradiation is so large that ir-
radiated mice may die within a few days after irradiation due to intestinal 
damage unless protected with AET. By this procedure, graft rejection by the 
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    Table 6. Survival rate of AET protected, gamma-irradiated and HBM treated mice. 
                         No. of  survival/No. of irradiated (at days) % survival 
                    7 14 21 30 60 21 day
  AET (6.5 mg)+1300 r T : 11/14 6/14 2/14 0/1416 
    dd/s<—----Na2C5/9 5/9 2/9 2/9 1/9 22 
  AET (6.5 mg)+1500 r T : 12/12 12/12 12/12 7/12 1/12 100 
   dd/s<---------Na, C : 3/5 3/5 2/5 1/540 
  AET (6.5 nig)+1300 r T : 3/8 1/8 1/8 1/8 1/8 12 
4W
aistar C : 5/9 5/9 2/9 2/9 2/9 22 
   T : AET+gamma rays+HBM or RBM. 
   C : AET+gamma rays. 
host may be prevented to develope due to severer damage of antibody forming 
cells of the host. The result is shown in Table 6. Although AET plus 1300 r 
may not be sufficient to depress immunological competence, AET plus 1500 r seems 
sufficient as shown by 100921 day survival. However, subsequent 30 or 60 day 
survival was low as that in secondary disease. Appropriate administration of 
AET to both the donor and recipient in the same experiment would give good 
initial 14 day and subsequent 30 or 60 day survival and experiments based on 
this assumption is under way. 
    VIII. Long Term Observation of Mice Lethally Irradiated with Gamma-Rays 
         under high Dose Rate and Treated with IBM 
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            Fig. 9. Survival rate of 900 r+IBM mice (long term observation). 
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        Fig. 10. Body weight changes of 900 r+IBM mice (long term observation). 
       Table 7. Main autopsy findings in 900 r+IBM mice (long term observation). 
                                       No. of r-rays+IBM/34 No. of control/ 21
     1) Neoplasma 
  Breast04 
 Lung31 
  Ovary20 
        Hematopoietic organ (Leukemia) 10 
  Stomach01 
  Orbit01 
     2) Infection 
  Lung104 
  Liver22 
      Kidney (Pyelonephritis)10 
  Ovary10 
     Generalized abscess10 
     3) Others 
    Nephrosclerosis80 
      Marked pulm. congestion10 
       Splenic bleeding & rupture 10 
Pulm. vein thrombosis10 
      Calcification of heart50 
other than those of the hematopoietic system. The bodily growth is retarded and 
survival time is shorter in the gamma-irradiated and IBM treated female mice 
than those in non-irradiated and non-IBM treated control mice (Figs. 9 and 10). 
Histologically, increase in incidence of nephrosclerosis and myocardial calcifica-
tion were found in irradiated and IBM treated mice (Table 7). Another kind of 
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control mice, namely, non-irradiated but IBM injected mice, and the mice, ir-
radiated twice each followed by IBM treatment, are now under observation and 
final results in regard to late radiation effects will be  reported'°. 
   The authors are indebted to Professor G. Wakisaka, M. D. for his sugges-
tions and advices in carrying out the study reported here, and thanks are ex-
tended to Mr. Rintaro Katano of the Institue for Chemical Research of Kyoto 
University for his kindness in frequently operating the Co60 irradiation facility. 
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